Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.70 |
| ▸ | BRAF | P15056 | 6/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.62 |
| ▸ | KDR | P35968 | 8/20 | 0.62 |
| ▸ | TEK | Q02763 | 2/20 | 0.58 |
| ▸ | JAK3 | P52333 | 5/20 | 0.41 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.37 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2265296 | 0.89 | LCK (0.70) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL5471596 | 0.88 | LCK (0.54) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL2264401 | 0.87 | BRAF (0.81) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL2264137 | 0.87 | LCK (0.67) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL11888995 | 0.86 | BRAF (0.68) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL2265281 | 0.86 | LCK (0.70) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL11889149 | 0.85 | LCK (0.75) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL22025872 | 0.85 | LCK (0.69) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL2265776 | 0.85 | LCK (0.69) | LCKBRAFMAPK14KDRTEK | |
| SCHEMBL2263470 | 0.85 | LCK (0.69) | LCKBRAFMAPK14KDRTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | claimed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | claimed |
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | LCK 392/4885BRAF 1/4885MAPK14 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.